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Abstract 27 
 28 
Objectives: We aimed to examine the declaration of interests (DOI), management of conflict of interest (COI), and 29 
the funders for World Health Organization (WHO) guidelines.  30 
Study Design and Setting: We examined all Guidelines Review Committee (GRC)-approved WHO guidelines 31 
published in English from January 2007 (inception of the GRC) to November 2016. We obtained a list of all such 32 
guidelines from the GRC Secretariat. Characteristics of guidelines including funders and individual contributors’ 33 
DOI were independently extracted by two researchers. Binary logistic regression was used to assess the association 34 
between declarations and the number of organizations involved in development.   35 
  36 
Results: 176 guidelines fulfilled inclusion criteria, encompassing 14 clinical or public health fields. Funders were 37 
reported in 128 (73%) of the guidelines: the most common were governments. DOI for external contributors were 38 
reported in 157 (89%) of the guidelines: 75 (48%) indicated no contributors with COI, 57 (36%) reported 39 
contributors with COI, and 25 (16%) reported collecting DOI but not whether COI existed. Financial COI were 40 
reported more frequently than nonfinancial COI. Of 57 guidelines that reported COI, 45 (79%) indicated how the 41 
COI were managed. 42 
Conclusion: The majority of WHO guidelines reported their funding sources, and the DOI and COI of external 43 
contributors in their guideline documents. However, there is a need for improvement, in particular for reporting of 44 
funders and their role, declaration processes, and management of COI.  45 
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Background 48 
 49 
Conflicts of interest (COI) - personal, organizational and financial factors which may affect the objectivity and 50 
independence of guideline contributors – are a potential source of bias in the development of clinical practice 51 
guidelines (CPGs) [1,2]. COI occur when professional judgment concerning a primary interest (such as the validity 52 
of research) tends to be unduly influenced by a secondary interest (such as financial gain) [3]. Secondary interests 53 
can be classified as financial and nonfinancial, and include interests directly or indirectly (e.g., through relatives 54 
and close friends) related to the guideline contributor. Financial interests include shares or bonds in a commercial 55 
entity, personal financial gain (payment for work or research, consulting income or honoraria), gifts, proprietary 56 
interests and patents related to the topic, and grants or fellowships from a commercial entity that has an interest in 57 
the subject-matter of the guideline. In addition to the financial interests of individual contributors, funding for the 58 
guideline itself may also be a source of COI[4]. Non-financial interests of guideline contributors are also important 59 
and include previously published research related to the potential recommendations in guidelines, and personal 60 
political, religious or ideological beliefs that might influence evidence assessment and recommendation 61 
development [5-8]. There is no universally agreed upon taxonomy and management strategy for non-financial 62 
interests, which thus can be particularly challenging to manage [9].  63 
 64 
Research findings are associated with the COI of authors and funders [10-17], thus management of COI of 65 
guideline contributors is critical to ensure the validity of recommendations in guidelines. Financial relationships 66 
between guideline organizations and biomedical companies are common but declarations of interest (DOI; the 67 
declaration of all potentially relevant secondary interests) are infrequently reported in guidelines [18-21]. Even 68 
when financial sponsorships are disclosed, few studies described the role of sponsors [10, 22,23]. 69 
 70 
The World Health Organization (WHO) produces guidelines to inform various stakeholders in the 194 71 
Member States of the United Nations. These guidelines provide information about what policy-makers, healthcare 72 
providers or patients should do, assist in making choices between different interventions that have an impact on 73 
public health and resources, and help health care providers and recipients and other stakeholders to make informed 74 
decisions [6]. WHO has clear requirements for DOI and assessment of COI of contributors to its information 75 
products including guidelines, taking into account both financial and nonfinancial interests [6,24]. The WHO 76 
Guidelines Review Committee (GRC) was established in 2007 to ensure the use of internationally accepted best 77 
practice in WHO guidelines. The GRC critically reviews planning protocols and final versions of guidelines, and 78 
ultimately approves documents that meet the Organization’s standards, including those related to COI [25]. 79 
 80 
The objective of this study was to examine DOI, COI, and funders reported in WHO guidelines, and the 81 
potential association between the reporting of DOI and whether WHO was the sole developer of a guideline.  82 
 83 
 84 
Methods  85 
Eligibility criteria and study selection 86 
We included all GRC-approved, WHO guidelines published in English from January 2007 to November 2016, 87 
including those developed in collaboration with other organizations. We obtained a list of all such guidelines from 88 
the GRC Secretariat, and downloaded documents from the WHO website 89 
(http://www.who.int/publications/guidelines/en/). We included only the latest English-language version of each 90 
guideline. The full text of each guideline was independently screened by two researchers (XQW and QFW); 91 
 4 
disagreements regarding inclusion were resolved by discussion or consultation with a third researcher (YLC). 92 
 93 
Data Extraction and analysis  94 
Data were independently extracted by two researchers (HXZ and RL) and disagreements were resolved by 95 
discussion or consultation with a third researcher (YLC). Referring to the requirements of WHO [5], the following 96 
data were extracted: 1) title, developers, year, topic(s); 2) funders, including their role in the development process; 97 
3) DOI, including information on who declared their interests, and the methods and processes that were used to 98 
collect, evaluate, and report them; and 4) COI, including information on who declared them, their type (financial or 99 
nonfinancial), who assessed them, and how they were managed.  100 
 101 
WHO, together with the other organizations involved in the development of a guideline, generally need to 102 
form four groups of contributors to complete the work: the steering group, the guideline development group, the 103 
external reviewer group, and the systematic review team. We investigated whether WHO guidelines reported DOI 104 
for all of these groups. DOI refers to declaration of all potentially relevant secondary interests, for example patent 105 
or stock ownership or prior authorship of a technical report on the same topic for the another group [24]. COI refers 106 
to the judgement that a declared secondary interest could potentially influence the guideline development process 107 
or outcomes, or the credibility of the final product. For example, if a guideline contributor declared owning stock in 108 
a drug manufacturer and that drug is being examined in a guideline, that is a COI. On the other hand, if the declared 109 
stock has no relevance whatsoever to the guideline at hand, that DOI is not a COI.   110 
 111 
After extracting DOI from each guideline, we report if and how declared interests were assessed, and how 112 
conflicts, if any, were managed. If the guideline only reported DOI but did not indicate that the declared interests 113 
were assessed, we considered the situation to be “unclear”.  We then examined DOI and the assessment process 114 
across publication years. 115 
 116 
We used binary logistic regression to assess the potential association between WHO as the sole developer of 117 
guidelines (versus having multiple contributors) (independent variable) and reporting of DOI in guideline 118 
documents or their annexes (dependent variable). We hypothesized that guidelines that were developed 119 
collaboratively by several organizations may have lower rates of reporting DOI and COI management than 120 
guidelines developed by WHO because the other organizations may have less robust COI policies and practices. 121 
The regression analysis was conducted in SPSS Statistics 22 (SPSS Inc., Chicago, IL, USA).  122 
 123 
Results 124 
We identified 208 guidelines approved by the GRC since its inception. Of these, 32 guidelines were excluded 125 
because they had been superseded by newer versions or were not published in English. Thus 176 guidelines 126 
fulfilled eligibility criteria (Fig. 1).   127 
 128 
The characteristics of included guidelines are shown in Table 1. The number of guidelines published annually 129 
ranged between 6 and 29. Of the guidelines, 143 (81%) were developed solely by WHO, including its regional 130 
offices; the remainder were developed in partnership with external organizations.  131 
 Table 1. Characteristics of the included guidelines (n=176) 132 
Characteristic  Number (%) 
Publication year 2008 22 (13) 
 2009 29 (16) 
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 2010 21 (12) 
 2011 29 (16) 
 2012 20 (11) 
 2013 17 (10) 
 2014 16 (9) 
 2015 16 (9) 
 2016 6 (3) 
Developers  Developed by WHO 143 (81) 
 Developed by WHO in partnership with other 
organizations 
33 (19) 
Type of funder* No information on funding sources 48 (27) 
 Governments  105 (60) 
 WHO and its programs 25 (14) 
 International non-profit organizations  24 (14) 
 Foundations  21 (12) 
 Institutes or societies 15 (9) 
 Other (universities or hospitals)   3 (2) 
Number of funders No information on funding resources 48 (27) 
 1 55 (32) 
 ≥2 73 (41) 
Role of funders* No information  120 (68) 
 None 7 (4) 
 Unspecified support for guideline development  26 (15) 
 Meeting support 12 (7) 
 Support the evidence review(s) 7 (4) 
 Support publication and printing 7 (4) 
 Provide technical support and consultation 3 (2) 
 Appoint observers 1 (1) 
 Supply products 1 (1) 
 Edit  1 (1) 
Topic Infectious diseases** 76 (43) 
 Maternal and child health 36 (20) 
 Nutrition, chronic disease prevention  21 (12) 
 Cancer 6 (3) 
 Mental health and neurologic disorders 6 (3) 
 Environment and health 6 (3) 
 Smoking and substance abuse 5 (3) 
 Health policy 5 (3) 
 Public health emergencies including pandemics  4 (2) 
 Food and health 3 (2) 
 Non-communicable diseases 3 (2) 
 Medical devices  3 (2) 
 Disability  1 (1) 
 Violence  1 (1) 
 6 
* One guideline could be included in multiple categories.  133 
** 63 focused on TB or HIV. 134 
 135 
Funding sources for guideline development were reported in 128 (73%) of the guidelines. Of guidelines 136 
reporting funding sources, 55 (43%) were supported by one source and 73 (57%) received funding from two or 137 
more sources. The funders contributing to the greatest number of guidelines were governments (105, 82%), 138 
followed by non-profit organizations (24, 19%) and the WHO itself (25, 19%).  Only 51 (40%) of the 128 139 
guidelines reporting funding sources described the role of the funders. None of the included guidelines reported 140 
receiving funding from commercial entities. 141 
 142 
A total of 157 (89%) guidelines reported the declared interests of external contributors (contributors who are 143 
external to WHO and participate in the guideline development process) (Fig. 1). Of the 157 guidelines, 97 (62%) 144 
reported the methods used to collect DOI (56 used a declaration form and 41 used a form plus verbal declaration), 145 
and 90 (57%) presented the process for assessing DOI (reported who assessed the DOI and by what criteria).  146 
Seventy-five (48%) of the 157 guidelines that reported DOI clearly indicated that no COI existed, and 57 (36%) 147 
reported one or more COI. The remaining 16% of guidelines provided the DOI without reporting if COI existed. Of 148 
the 57 guidelines that reported COI, 45 (79%) presented the management decisions that were made to deal with the 149 
COI (Table 2). 150 
 151 
Table 2. The management decisions for conflicts of interest 152 
Decision 
Number 
(%) 
The contributor should not contribute to deliberations on or formulation of the recommendations 34 (75) 
Requires no action beyond declaration at the meeting and reporting in the final guideline 14 (31) 
The contributor should not participate in evidence evaluation 8 (18) 
The contributor should not provide comments on the final document 4 (9) 
The contributor should not participate in relevant discussions and meetings 5 (11) 
The contributor should not chair the screening discussion or identify the main sources of data 2 (4) 
The contributor should not participate in developing provisional framework 1 (2) 
Note: The total number is the 45 guidelines that reported this information. 153 
 154 
Of the 57 guidelines reporting COI, 37 (65%) reported both financial and nonfinancial interests among the 155 
external contributors. The three most commonly reported types of COI were personal financial gain, personal 156 
research support, and participation in related research projects or presentations on related topics (Table 3). 157 
 158 
Table 3. Types of conflicts of interest  159 
Item (n, %) Types of conflicts of interest  Number (%) 
Financial  
(48, 86%) 
Personal financial gain a 33 (58) 
Personal research support b 40 (70) 
Personal or organizational financial aid or scholarship  7 (12) 
Proprietary interests and patents 2 (4) 
Stock, shares or bonds 9 (16) 
Nonfinancial 
(44, 79%) 
Occupation or position, such as acting as chair or unpaid consultant for 
relevant organizations  
29 (51) 
 7 
Participation in related research projects or presentations on related 
topics  
35 (61) 
Personal political, religious or ideological beliefs 0 (0) 
a Personal financial gain includes compensation, remuneration, travel allowance and other financial gain. 160 
b Research support includes direct investment, device or product donation and other forms of support. 161 
Note: The total number (n) is the 57 guidelines that reported this information. Different types of conflict of interest can exist in the 162 
same guideline. 163 
 164 
A total of 145 guidelines (82%) reported the specific individuals or groups who declared their interests (Table 165 
4). Members of the guideline development group (54, 31%), external or peer reviewers (48, 27%), and experts 166 
participating in meetings where recommendations were formulated (32, 18%) were the most frequent groups to 167 
provide DOI. DOI from the systematic review teams and from the guideline methodologists were rarely reported. 168 
   169 
Table 4. Contributors declaring interests 170 
Options n (%) 
Guideline development group 54 (31) 
External reviewers or peer reviewers  48 (27) 
Experts participating in meetings 32 (18) 
Expert groups 31 (18) 
Counselors/technical experts 24 (14) 
Contributors/participants 11 (6) 
Working groups 7 (4) 
Core groups/members 4 (2) 
Authors 4 (2) 
Systematic review/ evidence groups 3 (2) 
Methodologists 3 (2) 
Steering groups 3 (2) 
Observer, writing group, editor, external expert 8 (4) 
Note: Because the labels for contributors varied across guidelines, some of these groups likely have similar roles to each other (e .g., 171 
guideline development group members and experts participating in meetings). The total number (n) is the 145 guidelines that reported 172 
this information. 173 
 174 
Reporting of how DOI were collected and the process to assess DOI improved substantially between 2009 and 175 
2011, and stayed relatively stable thereafter. Reporting of the judgements about whether COI existed changed little 176 
over time (Fig. 2). When WHO was the sole author of a guideline, DOI was reported more frequently (131/143, 177 
92%) than for guidelines that were co-developed with other organizations (26/33, 79%) (odds ratio [OR]= 2.9, 95% 178 
confidence interval [CI] 1.1-8.2). The rates of DOI remained stable around 90% over time, except in 2010 when 179 
only 67% reported DOI.  180 
 181 
Discussion   182 
The majority of WHO guidelines reported their funding sources, however less than half presented the role of 183 
funders. Nearly 90% of the guidelines reported DOI, however of guidelines collecting DOI 38% did not provide 184 
details on how DOI were collected and nearly half did not report how DOI were assessed.  In addition, 21% of 185 
guidelines that reported one or more COI gave no information on how COI were managed. Seventeen percent of 186 
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guidelines providing DOI did not report if COI existed. The most commonly reported type of COI was personal 187 
financial gain, and guidelines developed solely by WHO tended to report DOI more frequently than those 188 
co-developed with other organizations, although the difference was small.  189 
 190 
Guideline development usually requires significant financial resources, and WHO staff may have to seek 191 
external funding in addition to mobilizing internal resources. External funding can, however, lead to biased 192 
recommendations [4,12,26] and thus many guideline developers and organizations producing systematic reviews 193 
set restrictions on the sources of funding. For example, the American Thoracic Society refuses any outright 194 
sponsorship [27] and the Cochrane Collaboration does not accept support for reviews from commercial sponsors 195 
that have a financial interest in the outcome [28]. Similarly, WHO does not permit guidelines funded by commercial 196 
entities [6]. Trustworthy guidelines must be transparent, including reporting of all funders [29, 30]. However, 197 
almost one-third of WHO guidelines did not provide this information, and less than half of those reporting funding 198 
sources described the exact role of funders.  199 
 200 
Organizations including the Guidelines International Network [31], the New Zealand Guidelines Group [32], 201 
the British HIV Association [33], the U.K. National Institute for Health and Clinical Excellence [34], and WHO [6] 202 
all explicitly require DOI and the assessment of all disclosures for potential COI, followed by appropriate 203 
management of any conflicts. Standardized and complete reporting of DOI, COI and their management should be 204 
further improved at WHO. WHO requires the guideline development group, external reviewers, systematic review 205 
team and methodologists to declare their interests [6], but the results showed that the actual DOI varied greatly 206 
across contributors and guidelines.  The labelling of guideline contributors varies across guidelines, which makes 207 
it difficult for end-users to understand the types of contributors and to compare rates of DOI and COI management 208 
across guidelines. In addition, there is no specific place for DOI reporting in WHO guidelines – the reader may 209 
have to look through the entire document and its appendices to find this information. 210 
 211 
As this topic now receives more attention, DOI and COI are increasingly being reported in guidelines. George 212 
and colleagues reported in 2001 that only 3.7% of the included guidelines reported DOI information [35].  A 2012 213 
study showed that only 60% of guidelines included in the US National Guidelines Clearinghouse (NGC) reported 214 
DOI and reporting of the management of COI was poor [20]. A more recent (2016) study of NGC guidelines 215 
showed that 65% of the guidelines reported DOI [21]. The results of our study suggest that reporting of DOI and 216 
COI management at WHO is better than that for other guideline developers: this may reflect rigorous 217 
implementation of the WHO COI policy and oversight by the GRC.  218 
 219 
Financial COI can substantially affect research findings, usually in favor of commercial entities 220 
[11-13,16,36,37].  The effects of nonfinancial interests on research and decision-making are less clear-cut and 221 
there is debate about whether or not such interests are an important source of bias [9].  Many researchers do feel 222 
that nonfinancial COI can influence primary research, synthesis, and recommendations in guidelines [38-40]. One 223 
study in fact suggests that nonfinancial COI might have an even greater impact on patients or volunteers [41], and a 224 
survey reported that grant reviewers were more concerned about non-financial COI than financial interests [42]. 225 
The management of nonfinancial COI is particularly challenging, as all individuals, including content experts, have 226 
such interests [43,44]. The only approaches to minimize the risk of bias from such interests are to try and balance 227 
the perspectives, experiences, values and viewpoints across individuals contributing to the recommendations [5].  228 
Both financial and nonfinancial COI were frequently reported in WHO guidelines, suggesting that WHO staff are 229 
aware of the importance of both types of interests, and complete reporting enables end-users to appropriately 230 
 9 
interpret the guidelines.  231 
 232 
The number of organizations involved in guideline development may influence DOI reporting [20]. We found 233 
that guidelines developed solely by WHO reported DOI more often than those co-developed with other 234 
organizations. However, the difference was small and the statistical analysis was not able to provide strong 235 
evidence of a true association. The small difference may be related to WHO’s uniform requirements, regardless of 236 
the number of collaborators. We also explored changes in reporting over the 9-year period of guideline 237 
development since inception of the GRC. Although the rates of reporting DOI remained stable across the years, and 238 
details of DOI collection and management were reported more frequently in recent years. This may be partly 239 
attributed to continuous advances in the requirements for guideline development both internationally and at WHO 240 
[6,45-47].   241 
 242 
Strengths and limitations 243 
To our knowledge, this is the first study to evaluate the reporting of DOI and COI of guidelines related to both 244 
clinical practice and public health or health policy. Although the same principles for developing trustworthy 245 
guidelines apply to WHO guidelines as to clinical practice guidelines, WHO guidelines (which are usually 246 
developed for a global audience) may differ with respect to funding sources, diversity of end-users, the population 247 
focus, financial constraints, and the need to address issues of equity and human rights and incorporate issues related 248 
to social determinants of health. Thus the results of examination of other clinical practice guidelines may not 249 
necessarily be applicable to WHO guidelines.  We obtained guidelines from the WHO website and the GRC 250 
Secretariat in order to ensure a comprehensive list. We assessed the reporting of DOI and COI of WHO guidelines 251 
according to WHO’s own requirements, which are consistent with those of the US Institute of Medicine [29].  252 
 253 
Our study results are based only on information reported in the guidelines. The completed DOI forms are not 254 
publicly available (only a summary of DOI and COI is published in WHO guidelines), and we did not contact 255 
guideline authors for further information, and there are data to suggest that self-report of interests is frequently 256 
inaccurate [48,49].  In addition, we did not examine differences in reporting across topics because for most topics 257 
only a small number of guidelines were published.  There may be variation across the technical units at WHO, as 258 
experience and training levels may differ.  These questions should be further investigated in the future.  259 
 260 
 261 
Conclusion 262 
The identification and management of COI, particularly nonfinancial interests, are challenging for all 263 
guideline developers; nonetheless the collection and assessment of DOI and the management plan for any COI 264 
should be consistently reported in all guidelines. The majority of WHO guidelines performed relatively well with 265 
respect to reporting of funders, DOI and COI of external contributors in their guideline documents. This may be 266 
related to the quality assurance process at WHO implemented by the GRC, and the careful attention paid to this 267 
issue by WHO staff. However, there is a need for improvement, in particular for reporting the role of funders, 268 
declaration processes, and management of COI. WHO and the guideline community need to continue to seek more 269 
efficient and effective approaches for identifying, quantifying and minimizing potential sources of bias in guideline 270 
development.   271 
 272 
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